The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer.
 
Tomoya Yokota
Honoraria - Bayer; Eisai; Merck Serono; Niphix; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst)
 
Ken Kato
Speakers' Bureau - Lilly Japan; Taiho Pharmaceutical
Research Funding - Merck Sharp & Dohme; Ono Pharmaceutical; Shionogi
 
Yasuo Hamamoto
No Relationships to Disclose
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Hirofumi Ogawa
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
Hiroki Hara
Consulting or Advisory Role - Ono Pharmaceutical
Speakers' Bureau - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takashi Ura
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Janssen; Merck Serono; Taiho Pharmaceutical; Takeda
 
Takashi Kojima
Research Funding - Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Keisho Chin
No Relationships to Disclose
 
Shuichi Hironaka
Honoraria - Taiho Pharmaceutical; Yakult Honsha
 
Takayuki Kii
No Relationships to Disclose
 
Yasushi Kojima
Speakers' Bureau - Chugai Pharma; Takeda
Research Funding - Kyowa Hakko Kirin (Inst); NanoCarrier (Inst)
 
Yasunori Akutsu
No Relationships to Disclose
 
Hisayuki Matsushita
No Relationships to Disclose
 
Kentaro Kawakami
No Relationships to Disclose
 
Keita Mori
No Relationships to Disclose
 
Yushi Nagai
No Relationships to Disclose
 
Chika Asami
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)